Page 3 - Michael Dutra News Today : Breaking News, Live Updates & Top Stories | Vimarsana

TG Therapeutics announced that its existing term loan facility agreement with Hercules Capital has been amended to increase the size of the facility to $200 million, with $70 million funded at closing. Michael S. Weiss, Chairman and Chief Executive Officer of TG Therapeutics stated, “We are pleased to announce the expansion of our term loan...

Axsome Therapeutics announced that its existing term loan facility agreement with Hercules Capital has been amended to increase the size of the facility to $300 million, and the amount immediately available upon U.S. Food and Drug Administration (FDA) approval of AXS-05 for major depressive disorder to $100 million, at the Company’s option. The...